Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Invasive Breast Cancer (Stage I-III)|Ductal Carcinoma in Situ|Lobular Carcinoma in Situ|Lobular Carcinoma|Fatigue Related to Cancer Treatment
Interventions: DRUG: Naltrexone|DRUG: Sugar Pill
Sponsor: Dana-Farber Cancer Institute
Collaborators: National Cancer Institute (NCI)